Literature DB >> 9690041

alpha-Melanocyte-stimulating hormone and acute renal failure.

Y Kohda1, H Chiao, R A Star.   

Abstract

alpha-Melanocyte-stimulating hormone (MSH) is an endogenous anti-inflammatory cytokine that inhibits all major forms of inflammation, alpha-MSH level is increased at sites of inflammation in humans, and is produced in the pituitary and in macrophages. The effects of alpha-MSH are mediated by melanocortin receptors found on macrophages, neutrophils, and renal tubules. alpha-MSH inhibited ischemic acute renal failure in mice and rats, even when started 6 h after injury. alpha-MSH acts, in part, by inhibiting the maladaptive activation of genes that cause inflammatory and cytotoxic renal injury. However, alpha-MSH is effective even in the absence of neutrophils, suggesting that alpha-MSH also acts directly on renal tubules.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9690041     DOI: 10.1097/00041552-199807000-00011

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  13 in total

Review 1.  The renaissance of corticotropin therapy in proteinuric nephropathies.

Authors:  Rujun Gong
Journal:  Nat Rev Nephrol       Date:  2011-12-06       Impact factor: 28.314

2.  Exogenous acid fibroblast growth factor inhibits ischemia-reperfusion-induced damage in intestinal epithelium via regulating P53 and P21WAF-1 expression.

Authors:  Wei Chen; Xiao-Bing Fu; Shi-Li Ge; Wen-Juan Li; Tong-Zhu Sun; Zhi-Yong Sheng
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

3.  The reduction of Na/H exchanger-3 protein and transcript expression in acute ischemia-reperfusion injury is mediated by extractable tissue factor(s).

Authors:  F Di Sole; Ming-Chang Hu; Jianning Zhang; Victor Babich; I Alexandru Bobulescu; Mingjun Shi; Paul McLeroy; Thomas E Rogers; Orson W Moe
Journal:  Kidney Int       Date:  2011-08-03       Impact factor: 10.612

Review 4.  Translating Knowledge Into Therapy for Acute Kidney Injury.

Authors:  Mark de Caestecker; Raymond Harris
Journal:  Semin Nephrol       Date:  2018-01       Impact factor: 5.299

Review 5.  Lung injury following acute kidney injury: kidney-lung crosstalk.

Authors:  Kent Doi; Tomoko Ishizu; Toshiro Fujita; Eisei Noiri
Journal:  Clin Exp Nephrol       Date:  2011-06-01       Impact factor: 2.801

6.  AP214, an analogue of alpha-melanocyte-stimulating hormone, ameliorates sepsis-induced acute kidney injury and mortality.

Authors:  K Doi; X Hu; P S T Yuen; A Leelahavanichkul; H Yasuda; S M Kim; J Schnermann; T E N Jonassen; J Frøkiaer; S Nielsen; R A Star
Journal:  Kidney Int       Date:  2008-03-19       Impact factor: 10.612

Review 7.  Advances in pediatric acute kidney injury.

Authors:  Rupesh Raina; Ronith Chakraborty; Abhishek Tibrewal; Sidharth K Sethi; Timothy Bunchman
Journal:  Pediatr Res       Date:  2021-03-17       Impact factor: 3.756

8.  Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms.

Authors:  Jin Si; Yan Ge; Shougang Zhuang; Li Juan Wang; Shan Chen; Rujun Gong
Journal:  Kidney Int       Date:  2013-01-16       Impact factor: 10.612

9.  Effects of allopurinol and vitamin E on renal function in patients with cardiac coronary artery bypass grafts.

Authors:  Nader Nouri-Majalan; Ehsan Fotouhi Ardakani; Khalil Forouzannia; Hosein Moshtaghian
Journal:  Vasc Health Risk Manag       Date:  2009-06-07

10.  α-Melanocyte stimulating hormone treatment in pigs does not improve early graft function in kidney transplants from brain dead donors.

Authors:  Willem G van Rijt; Niels Secher; Anna K Keller; Ulla Møldrup; Yahor Chynau; Rutger J Ploeg; Harry van Goor; Rikke Nørregaard; Henrik Birn; Jørgen Frøkiaer; Søren Nielsen; Henri G D Leuvenink; Bente Jespersen
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.